PMV Pharmaceuticals

Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates

5 months ago

• Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials. • Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025. • PMV Pharmaceuticals' rezatapopt Phase 2 trial for TP53 Y220C-mutated solid tumors is on track, with an interim analysis expected by mid-2025. • PMV Pharmaceuticals is collaborating with Foundation Medicine to develop a companion diagnostic for rezatapopt, a p53 Y220C reactivator.

PMV Pharma's Rezatapopt Shows Promise in TP53-Mutated Solid Tumors and AML/MDS

6 months ago

• PMV Pharmaceuticals' PYNNACLE trial advances with Rezatapopt monotherapy for TP53 Y220C mutated solid tumors, showing over 75% site activation across multiple regions. • A Phase 1b study will assess Rezatapopt with azacitidine for relapsed/refractory AML/MDS with TP53 Y220C mutation, beginning enrollment in early 2025. • Rezatapopt's exposure levels improved when taken with food, reducing gastrointestinal adverse events, supporting the 2000 mg QD dose in the PYNNACLE Phase 2 study.

PMV Pharmaceuticals Provides Update on PC14586 (Rezatapopt) Clinical Trials and Financial Status

7 months ago

• PMV Pharmaceuticals is advancing PC14586 (rezatapopt) in a Phase 2 monotherapy trial (PYNNACLE) for solid tumors with p53 Y220C mutations, with interim data expected by mid-2025. • The company discontinued the Phase 1b combination arm of the PYNNACLE trial, which evaluated rezatapopt with pembrolizumab (KEYTRUDA®). • Collaborations with MD Anderson and Memorial Sloan Kettering will support a Phase 1b study combining rezatapopt with azacytidine, starting in Q1 2025. • PMV's current funds should support operations through 2026, focusing on PC14586's clinical development and regulatory milestones.

Rezatapopt Shows Promise in Targeting Previously 'Undruggable' p53 Mutation in Advanced Solid Tumors

10 months ago

• Rezatapopt, a first-in-class p53 Y220C reactivator, targets the once 'undruggable' p53 Y220C mutation, prevalent in about 1% of all cancers, offering a tumor-agnostic approach. • Phase 1 data from the PYNNACLE study demonstrated an overall response rate of 34% in efficacy-evaluable patients treated with rezatapopt monotherapy across various advanced solid tumors. • The agent exhibited a favorable safety profile, with mostly grade 1 or 2 treatment-related adverse events, and manageable gastrointestinal toxicities when administered with food. • Phase 2 of the PYNNACLE study is underway, evaluating rezatapopt in specific cancer cohorts, with potential for accelerated approval based on promising initial results.